The CTL induction efficiency of survivin-C58 peptide was almost comparable to that of survivin-2B80-88 peptide, and it was noted that CTL could not be induced from PBMCs of oral cancer patients with stage I. These findings contrast with our previous report that survivin-specific CTLs were induced successfully from PBMCs of breast cancer patients and colorectal cancer patients with stage I [23]. The gene discussed is BIRC5; the disease is breast carcinoma.